Phase 2 N=35 Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Cushing's Syndrome
Primary: Percentage of Participants With One or More Adverse Events — 15; 18 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Number of Patients With Reactions of the Injection Site as an Assessment of the Tolerability — 3 Participants
Phase 2 N=366 Panblok H7 Vaccine Adjuvanted With AS03 or MF59
Influenza, Human
Primary: Solicited Local Reactogenicity Symptoms for Participants Given Adjuvant AS03 — 42; 44; 36 Participants
Phase 2 N=138 Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine
Eastern Equine Encephalitis
Primary: Subject Response Rates for PRNT80 Titers — 39; 28; 48; 79 Participants
Phase 2 N=69 A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
Non-Small Cell Lung Cancer (NSCLC)
Primary: Progression-free Survival Rate at Four Months (PFS4) — 27.3; 15.8; 26.1 percentage of participants
Phase 2 N=17 Riociguat in Scleroderma Associated Digital Ulcers
Scleroderma · Digital Ulcers
Primary: Change From Baseline to End of Double-blind Treatment (Week 16) in Digital Ulcer Net Burden — -1.22; -0.98 ulcers — p=0.70
Phase 2 N=45 Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid
Primary Biliary Cholangitis (PBC)
Primary: Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) Levels at Week 12 (Endpoint) — -48.264; -40.640; 3.190 Percent change — p=<0.001
Phase 2 N=204 Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia
Gout and Hyperuricemia
Primary: Percent Changes of Serum Uric Acid Levels From Baseline Levels — -30.93; -49.91; -54.32; -2.05 Percent change — p=<0.0001
Phase 2 N=28 An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia (CLL)
Primary: Overall Response Rate, as Per the IWCLL 2008 Response Criteria — 1; 13; 14 Participants
Phase 2 N=32 Investigation of Mesenchymal Stem Cell Therapy for the Treatment of Osteoarthritis of the Knee
Knee Osteoarthritis
Primary: Knee Injury and Osteoarthritis Outcome Score — 16.71; 10.93; 14.00; 10.47 score on a scale
Phase 2 N=60 The Efficacy and Safety Study of Tung's Acupuncture for Polycystic Ovarian Syndrome
Polycystic Ovarian Syndrome
Primary: Change in LH/FSH Ratio From Baseline to the End of Treatment — -0.66; -0.96 ratio
Phase 2 N=30 Efficacy, Safety, and Tolerability of HTS-519 Insert in Patients With Toenail Fungus of the Big Toenail
Onychomycosis
Primary: Treatment Related Adverse Events — 22; 8 Participants
Phase 2 N=52 Long-Term Assessment of Remyelinating Therapy
Acute Optic Neuritis
Primary: FF-VEP Latency of the Affected Eye as Compared to the Baseline of the Fellow Eye at 2 Years (+ up to 12 Months) After the Last Study Visit Assessment (Week 32) in RENEW…
Phase 2 N=52 Modulation of Lung Injury Complicating Lung Resection
Acute Lung Injury
Primary: Post-operative Plasma IL-6 — 126; 111 pg/ml — p=0.09
Phase 2 N=43 Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
Urinary Tract Urothelial Carcinoma
Primary: Number of Participants With Complete Response at 3 Months — 26 Participants